Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2011

Open Access 01-12-2011 | Rapid communication

High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma

Authors: Wu ZL, Song YQ, Shi YF, J Zhu

Published in: Journal of Hematology & Oncology | Issue 1/2011

Login to get access

Abstract

Background

The purpose of the study was to investigate the expression and prognostic value of STAT3 in diffuse large B-cell lymphoma (DLBCL).

Methods

Seventy-four DLBCL patients from 2001 to 2007 were reviewed in the study. The STAT3 expression in their tumor tissues was examined using the immunohistochemistry (IHC) method, and evaluated for its association with clinicopathological parameters.

Results

Strong nuclear staining of STAT3 and phosphorylated-STAT3tyr705 (P-STAT3) were observed in 19 cases (25.7%) and 24 cases (32.4%), respectively, and the expression levels were highly consistent between them (P = 0.001). The high nuclear expression of STAT3 was more frequent in the non-germinal center B cell-like (non-GCB) DLBCL than that in the GCB subtype, but not reaching significance (P < 0.061). The high nuclear expression of STAT3 was found to be correlated with poor overall survival (OS) (P = 0.005). Multivariate Cox regression analysis showed that the STAT3 expression was an independent prognostic factor for DLBCL patients regardless of CHOP or R-CHOP regimen used as the first-line therapy.

Conclusion

STAT3 is more frequently expressed in non-GCB DLBCL than that in GCB subtype, and its strong nuclear expression is correlated with poor OS in DLBCL.
Appendix
Available only for authorised users
Literature
1.
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, (Eds): 2008, World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon
2.
Harris N L, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC: A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994, 84 (5): 1361-1392.PubMed
3.
Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD, Connors JM: The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007, 109 (5): 1857-1861. 10.1182/blood-2006-08-038257.CrossRefPubMed
4.
Talaulikar D, Shadbolt B, Dahlstrom JE, McDonald A: Routine use of ancillary investigations in staging diffuse large B-cell lymphoma improves the International Prognostic Index (IPI). J Hematol Oncol. 2009, 22;2: 49-CrossRef
5.
Alizadeh A A, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000, 403: 503-11. 10.1038/35000501.CrossRefPubMed
6.
Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, López-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM, Lymphoma/Leukemia Molecular Profiling Project: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002, 346 (25): 1937-47. 10.1056/NEJMoa012914.CrossRefPubMed
7.
Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM: A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA. 2003, 100 (17): 9991-6. 10.1073/pnas.1732008100.PubMedCentralCrossRefPubMed
8.
Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M, MabThera International Trial Group: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006, 7 (5): 379-91. 10.1016/S1470-2045(06)70664-7.CrossRefPubMed
9.
Sehn L H, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, MacPherson N, O'Reilly S, Spinelli JJ, Sutherland J, Wilson KS, Gascoyne RD, Connors JM: Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005, 23 (22): 5027-33. 10.1200/JCO.2005.09.137.CrossRefPubMed
10.
Calo' V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N, Russo A: STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol. 2003, 197: 157-168. 10.1002/jcp.10364.CrossRef
11.
Chen Z, Han ZC: STAT3: a critical transcription activator in angiogenesis. Med Res Rev. 2008, 28 (2): 185-200. 10.1002/med.20101.CrossRefPubMed
12.
Zhou Jianbiao, Goh Boon-Cher, Daniel Albert, Chen Shing Chien: ABT-869, a promising multi-targeted tyrosine kinase inhibitor:from bench to bedside. J Hematol Oncol. 2009, 2: 33-46. 10.1186/1756-8722-2-33.PubMedCentralCrossRefPubMed
13.
Patrick Johnston, Yuan RuiRong, Cavalli Franco, Thomas Witzig: Targeted therapy of lymphoma. J Hematol Oncol. 2010, 3: 45-10.1186/1756-8722-3-45.CrossRef
14.
Turkson J: STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets. 2004, 8 (5): 409-22. 10.1517/14728222.8.5.409.CrossRefPubMed
15.
Lam LT, Wright G, Davis RE, Lenz G, Farinha P, Dang L, Chan JW, Rosenwald A, Gascoyne RD, Staudt LM: Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-B pathways in subtypes of diffuse large B-cell lymphoma. Blood. 2008, 111 (7): 3701-13. 10.1182/blood-2007-09-111948.PubMedCentralCrossRefPubMed
16.
Scuto A, Kujawski M, Kowolik C, Krymskaya L, Wang L, Weiss LM, Digiusto D, Yu H, Forman S, Jove R: STAT3 Inhibition Is a Therapeutic Strategy for ABC-like Diffuse Large B-Cell Lymphoma. Cancer Res. 2011, 71 (9): 3182-8. 10.1158/0008-5472.CAN-10-2380.PubMedCentralCrossRefPubMed
17.
Ding BB, Yu JJ, Yu RY, Mendez LM, Shaknovich R, Zhang Y, Cattoretti G, Ye BH: Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood. 2008, 111 (3): 1515-23.PubMedCentralCrossRefPubMed
18.
Rane SG, Reddy EP: Janus kinases: components of multiple signaling pathways. Oncogene. 2000, 19 (49): 5662-79. 10.1038/sj.onc.1203925.CrossRefPubMed
19.
Dechow T N, Pedranzini L, Leitch A, Leslie K, Gerald WL, Linkov I, Bromberg JF: Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci USA. 2004, 101 (29): 10602-7. 10.1073/pnas.0404100101.PubMedCentralCrossRefPubMed
20.
Baran-Marszak F, Boukhiar M, Harel S, Laguillier C, Roger C, Gressin R, Martin A, Fagard R, Varin-Blank N, Ajchenbaum-Cymbalista F, Ledoux D: Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma. Haematologica. 2010, 95 (11): 1865-72. 10.3324/haematol.2009.019745.PubMedCentralCrossRefPubMed
21.
Niu Guilian, Kenneth Wright: Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002, 21: 2000-2008. 10.1038/sj.onc.1205260.CrossRefPubMed
22.
Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H, Yu H: Stat3 mediates myeloid cell dependent tumor angiogenesis in mice. J Clin Invest. 2008, 118: 3367-3377. 10.1172/JCI35213.PubMedCentralCrossRefPubMed
23.
Kortylewski M, Xin H, Kujawski M, Lee H, Liu Y, Harris T, Drake C, Pardoll D, Yu H: Regulation of the IL-23 and IL-12 balance by Stat3 signaling the tumor microenvironment. Cancer Cell. 2009, 15: 114-123. 10.1016/j.ccr.2008.12.018.PubMedCentralCrossRefPubMed
24.
Wang L, Yi T, Kortylewski M, Pardoll D, Zeng D, Yu H: IL-17 can promote tumor growth through an IL-6/Stat3 signaling pathway. J Exp Med. 2009, 206: 1457-1464. 10.1084/jem.20090207.PubMedCentralCrossRefPubMed
25.
Cheng F, Wang HW, Cuenca A, Huang M, Ghansah T, Brayer J, Kerr WG, Takeda K, Akira S, Schoenberger SP, Yu H, Jove R, Sotomayor EM: A critical role for Stat3 signaling in immune tolerance. Immunity. 2003, 19: 425-436. 10.1016/S1074-7613(03)00232-2.CrossRefPubMed
26.
Yu H, Kortylewski M, Pardoll D: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nature Rev Immunol. 2007, 7: 41-51. 10.1038/nri1995.CrossRef
27.
Yin Q, Zha X, Yang L, Chen S, Zhou Y, Wu X, Li Y: Generation of diffuse large B cell lymphoma-associated antigen-specific Vα6/Vβ13+T cells by TCR gene transfer. J Hematol Oncol. 2011, 4: 2-9. 10.1186/1756-8722-4-2.PubMedCentralCrossRefPubMed
28.
Haura E B, Turkson J, Jove R: Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer. Nature Clin Pract Oncol. 2005, 2: 315-324.CrossRef
29.
Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related inflammation. Nature. 2008, 454: 436-444. 10.1038/nature07205.CrossRefPubMed
Metadata
Title
High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma
Authors
Wu ZL
Song YQ
Shi YF
J Zhu
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2011
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-4-31

Other articles of this Issue 1/2011

Journal of Hematology & Oncology 1/2011 Go to the issue

Letter to the Editor

Clinical observations on intensive immunosuppressive therapy combined with umbilical cord blood support for the treatment of severe aplastic anemia

Review

Unfolded protein response in cancer: the Physician's perspective

Case report

Acute myeloid leukemia of donor origin after allogeneic stem cell transplantation from a sibling who harbors germline XPD and XRCC3 homozygous polymorphisms

Short report

Impact of bile acids on the growth of human cholangiocarcinoma via FXR

Letter to the Editor

Frequency of intravascular large B-cell lymphoma in Japan: Study of the Osaka Lymphoma Study Group

Review

Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits